Ep. 85 - Stifel’s Opler on Trump 2.0's FDA & the Capital Markets
From The BioCentury Show · · 32 min
This plays from the publisher's own server. We do not host a copy.
Description
Notwithstanding the bad start that the Trump administration got off to on FDA, Tim Opler is optimistic that the agency will serve drug developers well, and sees enough good signals that the direction the agency is headed will not bring the difficult regulatory era that many in the industry feared. Opler, a managing director at Stifel, spoke to Editor in Chief Simone Fishburn on The BioCentury Show about why he’s optimistic about FDA, what he sees ahead for capital markets, competition in China, and three areas of innovation he’s focused on -- aging, women's health and the brain.
View full story: https://www.biocentury.com/article/656040
#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment #FDA
00:00 - Introduction 01:30 FDA under Trump 2.0 08:07 State of Capital Markets 13:13 China Competition 17:09 Innovation: Aging, Women’s Health & the Brain